Señales en vivo de KURA | Maximiza tus Ganancias con Getagraph.com

COMPRAR 105183 min ago

@ $19.65

Emitido: 14 feb 2024 @ 15:45

Retorno: 0.00%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: -2.04 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	543 365
Volumen promedio	1.14M
Capitalización de mercado	1.50B
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $-0.560 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.45
ATR14	$0.0160 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Doyle Thomas James	Sell	594	Common Stock
2024-01-29	Doyle Thomas James	Sell	761	Common Stock
2024-01-29	Doyle Thomas James	Sell	963	Common Stock
2024-01-29	Bair Teresa Brophy	Sell	2 053	Common Stock
2024-01-29	Ford Kathleen	Sell	1 496	Common Stock

INSIDER POWER
42.08
Last 95 transactions
Buy: 6 371 376 \| Sell: 2 723 562

Volumen Correlación

Largo: 0.46 (neutral)

Corto: -0.82 (strong negative)

Signal:(62.055) Neutral

Kura Oncology Inc Correlación

10 Correlaciones Más Positivas
RMRM	0.943
GAINL	0.888
LQDT	0.876
TRVN	0.857
SLNH	0.85
QTEK	0.834
SWVL	0.825
HYMC	0.824
VYNT	0.817
LITM	0.808

10 Correlaciones Más Negativas
FANH	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kura Oncology Inc Correlación - Moneda/Commodity

0.62
( weak )

0.55
( weak )

0.00
( neutral )

-0.02
( neutral )

-0.12
( neutral )

0.46
( neutral )

Kura Oncology Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-849 000 (0.00 %)
EPS:	$-2.08

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-759 000 (0.00 %)
EPS:	$-2.03

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.970

Financial Reports:

No articles found.

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.